Detailed definition
Estrogen modulates migraine through complex mechanisms involving cortical excitability, serotonergic signaling, and trigeminal sensitization. Premenopausally, many women have menstrual migraines triggered by the late-luteal estrogen drop. In perimenopause, estrogen volatility — high-low swings — often worsens migraine frequency and severity. After menopause, when estrogen stabilizes (lower but not fluctuating), migraine often improves. For women with migraine in perimenopause, treatment options include continuous low-dose estrogen (transdermal) to dampen volatility, standard migraine prevention (topiramate, beta-blockers, CGRP antagonists), and acute treatment. Migraine with aura is a relative contraindication to high-dose oral combined hormonal contraceptives because of stroke risk; standard low-dose menopausal HRT, particularly transdermal estradiol, is generally considered safer in migraine-with-aura.
Why it matters in menopause
For perimenopausal women whose migraines worsen, continuous low-dose transdermal estradiol can sometimes flatten the estrogen volatility that triggers migraines and produce meaningful improvement. Migraine with aura adds nuance to HRT route choice and dose.
Related terms
Sources
External references: Wikipedia.